Loading...

RIGL RIGEL PHARMACEUTICALS INC Product Launches 8-K Filing

RGL

RGL

RIGEL PHARMACEUTICALS INC

(RIGL)

2025 8-K

Rigel Financial Update

New Board Appointment

Business Update

Q3 2025 Results

Financial Statements

Equity Offerings

Financial Statements

Patent Settlement

Board Appointment

Financial Results

Financial Results

Clinical Trial Update

Q3 Financial Results

Director Resignation

Collaboration Agreement

Financial Results Announcement

Reverse Stock Split

Reverse Stock Split

Approval of 2018 Equity Inc...

Financial Results

Amendment to Credit and Sec...

Financial Results Announcement

Asset Purchase Agreement

Financial Results

Financial Results

Financial Results

Equity Incentive Plan Amend...

Financial Results

Financial Results Announcement

Resignation of Chief Medica...

Financial Results

External Links:

On December 7, 2025, Rigel Pharmaceuticals announced updated data from its Phase 1b study evaluating R289 in patients with lower-risk myelodysplastic syndrome, presented at the 67th ASH Annual Meeting.

AI Assistant

RIGEL PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.